We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Naturopathic Compound Suppresses Growth of Prostate Cancer Cell Cultures

By LabMedica International staff writers
Posted on 19 Apr 2011
A recent paper by cancer researchers working with prostate cancer cell cultures supports claims of the efficacy of a naturopathic formulation as an anticancer treatment.

Investigators at Indiana University (Indianapolis, USA) evaluated the effects of the dietary supplement ProstaCaid (PC), which contains mycelium from medicinal mushrooms (Ganoderma lucidum, Coriolus versicolor, Phellinus linteus), saw palmetto berry, pomegranate, pumpkin seed, green tea [40% epigallocatechin-3-gallate (EGCG)], Japanese knotweed (50% resveratrol), extracts of turmeric root (BCM-95), grape skin, pygeum bark, sarsaparilla root, Scutellaria barbata, eleuthero root, Job's tears, astragalus root, skullcap, dandelion, coptis root, broccoli, and stinging nettle, with purified vitamin C, vitamin D3, selenium, quercetin, citrus bioflavonoid complex, beta-sitosterolzinc, lycopene, alpha lipoic acid, boron, berberine and 3.3'-diinodolymethane (DIM). More...
The ingredients form a collection of the natural products best known to be rich in anti-inflammatory and antioxidant activities.

In the current study, which was published in the April 4, 2011, online edition of the International Journal of Oncology, the investigators exposed cultures of prostate cancer cells to PC and then evaluated its effects on gene expression, tumor growth, and tumor invasiveness.

They reported that PC treatment inhibited cell proliferation in the population of highly invasive human hormone independent PC-3 prostate cancer cells in a dose- and time-dependent manner. PC suppressed the metastatic behavior of PC-3 cells by the inhibition of cell adhesion, cell migration, and cell invasion. DNA-microarray analysis demonstrated that PC inhibited proliferation through the modulation of expression of CCND1, CDK4, CDKN1A, E2F1, MAPK6, and PCNA genes.

Senior author Dr. Daniel Silva, associate professor of medicine at Indiana University, said, "The formula we studied has been shown to inhibit growth of human androgen dependent as well as independent prostate cancer cells, and suppresses the metastatic potential of these cells. We were able to identify specific genes, which are responsible for growth of human prostate cancer cells and show, on the molecular level, how it affects the cancer cells. Natural compounds in this formula are known to be without the side effects associated with traditional cancer chemotherapy drugs.”

Related Links:
Indiana University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.